Mologen AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures, has received patent from the Japan Patent Office (JPO) for its invention of an "allogeneic tumour therapy". This cancer therapy is based on allogeneic, genetically modified cancer cells and can be used to treat various types of cancer.

The cell-based cancer therapy MGN1601, which is already in clinical development, is covered by this patent. As a result, Mologen now gains patent protection for its fundamental invention as well as for its specific product candidate MGN1601 on the important Japanese market. Mologen has already obtained patent protection for MGN1601in Europe, the USA and Russia.

The patent protection also covers the allogeneic cancer cell line on which the therapy is based and which Mologen has established in accordance with drug law specifications.

Dr Matthias Schroff, CEO of Mologen AG, stated: "I'm delighted that we are able to gradually extend our patent protection for MGN1601. The highly promising results of the latest study, published in November, also highlight the future importance of MGN1601 for us. Consequently, the plans for further clinical studies with this product candidate from our pipeline are progressing at maximum speed."

The principle of action of cell-based cancer therapy lies in generating a cross-reaction of the patient's immune system to the patient's own cancer cells once the immune system has learned what cancer cells typically look like via the reaction to genetically modified, foreign (allogeneic) cancer cells. The clinical phase I/II study, for which patient recruitment was terminated prematurely last year, showed that MGN1601 had an exceptional safety and tolerability profile. The first highly promising data on its efficacy have also been collected. Mologen AG is currently performing further investigations and analyses of the data obtained from the clinical study.

Mologen AG, a leading research company in the fields of DNA medicine and cell-based medicine, is concentrating systematically on reaching its goal of developing highly effective and safe drugs for the treatment of cancer.